<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531633</url>
  </required_header>
  <id_info>
    <org_study_id>201677</org_study_id>
    <nct_id>NCT02531633</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high
      affinity and specificity for binding to the human IL-6 molecule that may have therapeutic
      benefit in the treatment of giant cell arteritis (GCA) by interruption of multiple pathogenic
      pathways. Sirukumab inhibits IL-6-mediated signal transducer and activator of transcription 3
      (STAT3) phosphorylation, resulting in the inhibition of the biological effect of IL-6. This
      study will evaluate the efficacy and safety of sirukumab to characterize the benefit-to-risk
      profile of sirukumab in the treatment of active GCA. The study will be conducted in 2
      distinct parts (Part A and Part B) and consists of the following phases: Screening phase,
      Part A: 52-week double-blind treatment phase, Part B: 104-week extension phase with the
      option to receive open-label sirukumab based on disease status and a 16-week follow-up phase
      if applicable.

      Approximately 204 subjects with a diagnosis of GCA and active disease within 6 weeks of
      baseline will be randomized into Part A, the 52-week double-blind treatment phase, to receive
      one of two doses of sirukumab or placebo, each in addition to a pre-specified prednisone
      taper. The efficacy and safety of sirukumab in sustaining remission will be assessed at Week
      52. Subjects completing Part A of the study will be eligible to enter Part B, the 104-week
      extension phase, designed to investigate the long-term maintenance of remission and safety
      following cessation of sirukumab treatment and to assess long-term corticosteroid use.
      Subjects with active GCA at the end of Part A or those with new onset of GCA flare during the
      first 52 weeks of Part B will be eligible to receive open-label sirukumab. Subjects will need
      to have follow-up safety evaluations for at least 16 weeks after receiving the last dose of
      study drug, applicable only for those who are withdrawn prematurely from the study or whose
      open-label sirukumab treatment in Part B completes after Week 88.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in
    giant cell arteritis.
  </why_stopped>
  <start_date type="Actual">October 16, 2015</start_date>
  <completion_date type="Actual">October 10, 2017</completion_date>
  <primary_completion_date type="Actual">October 10, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in sustained remission at Week 52 for sirukumab (100 mg every 2 weeks [q2w] for 12 months) as compared to placebo, each administered in addition to a 6-month prednisone treatment regimen</measure>
    <time_frame>Week 52</time_frame>
    <description>Sustained remission at Week 52 is defined as having achieved all of the following: Remission by Week 12; Absence of disease flare following remission at Week 12 through Week 52; Completion of the assigned prednisone taper protocol; No requirement for rescue therapy any time through Week 52.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Cumulative prednisone doses in subjects treated with sirukumab plus prednisone</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Median and cumulative prednisone dose over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Proportion of subjects in sustained remission</measure>
    <time_frame>At Week 52 (Part A) and from Week 52 to Week 78 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Measure of remission rates over time</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Proportion of subjects in remission at all time points of assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Time to first GCA flare</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Time to first GCA flare after clinical remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp;amp; B: Number of disease flares per subject over time</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Safety: Incidence of adverse events</measure>
    <time_frame>52 Weeks (Part A) and 120 Weeks (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Safety: Incidence of corticosteroid-related adverse events</measure>
    <time_frame>52 Weeks (Part A) and 120 Weeks (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Composite of vital signs assessment as a measure of safety: blood pressure, pulse rate and temperature</measure>
    <time_frame>52 Weeks (Part A) and 120 Weeks (Part B)</time_frame>
    <description>Vital signs assessment will include systolic and diastolic blood pressure, pulse rate and body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Composite of clinical laboratory tests assessment as a measure of safety: clinical chemistry and hematology</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Clinical laboratory tests will include clinical chemistry and hematology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Assessment of Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Estimate of the magnitude of patient response to treatment at different time points by patient report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Pain assessment</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Average pain assessed by patient report of rating on score of 0 to 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Patient reported outcome of difficulties in 8 functional areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Patient report of elements of fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Assessment of steroid impact</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Patient assessment of the side effects and impact of steroids on GCA symptoms over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Assessment of quality of life using the 36-item Short Form Version 2 Acute (SF-36v2 Acute)</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Patient report of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Assessment of health status using the EuroQoL-5D (EQ-5D)</measure>
    <time_frame>52 Weeks (Part A) and 104 Weeks (Part B)</time_frame>
    <description>Patient report of health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacodynamics: Change from baseline in erythrocyte sedimentation rate (ESR) over time</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacodynamics: Change from baseline in serum C-reactive protein (CRP) over time</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetics: Serum concentrations of sirukumab</measure>
    <time_frame>Up to Week 44</time_frame>
    <description>Blood samples will be collected at Baseline (Week 0), Week 2, 4, 8, 12, 16, 20, 24, 28,and at Week 44 for determination for serum concentrations of sirukumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B: Immunogenicity: Serum anti-sirukumab antibodies</measure>
    <time_frame>52 Weeks (Part A) and 120 Weeks (Part B)</time_frame>
    <description>Blood samples will be collected at Baseline (Week 0), Week 24, 44, 52 of Part A and Baseline (Week 52 of Part A), Week 12, 52, 104 of Part B and at Follow up (Week 120) for determination of serum anti-sirukumab antibodies</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (6-month taper)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (3-month taper)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Sirukumab, Dose 2+prednisone (6-month taper)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Placebo to match sirutkumab+prednisone (6-month taper)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Placebo to match sirukumab+prednisone (12-month taper)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:Open-label sirukumab 100 mg SC (if applicable)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirukumab</intervention_name>
    <description>Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.</description>
    <arm_group_label>Part A: Sirukumab, Dose 2+prednisone (6-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (3-month taper)</arm_group_label>
    <arm_group_label>Part B:Open-label sirukumab 100 mg SC (if applicable)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (6-month taper)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match sirukumab</intervention_name>
    <description>Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.</description>
    <arm_group_label>Part A:Placebo to match sirukumab+prednisone (12-month taper)</arm_group_label>
    <arm_group_label>Part A:Placebo to match sirutkumab+prednisone (6-month taper)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).</description>
    <arm_group_label>Part A:Placebo to match sirukumab+prednisone (12-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 2+prednisone (6-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (3-month taper)</arm_group_label>
    <arm_group_label>Part A:Placebo to match sirutkumab+prednisone (6-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (6-month taper)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match prednisone</intervention_name>
    <description>Placebo to match prednisone will be provided as tablets.</description>
    <arm_group_label>Part A:Placebo to match sirukumab+prednisone (12-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 2+prednisone (6-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (3-month taper)</arm_group_label>
    <arm_group_label>Part A:Placebo to match sirutkumab+prednisone (6-month taper)</arm_group_label>
    <arm_group_label>Part A: Sirukumab, Dose 1+prednisone (6-month taper)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of GCA defined by the following Revised GCA Diagnosis Criteria:

        Age &gt;=50 years. History of ESR &gt;=50 millimeter/hour (mm/hour) or CRP &gt;=2.45
        milligram/deciliter(mg/dL).

        Presence of at least one of the following: Unequivocal cranial symptoms of GCA; Unequivocal
        symptoms of polymyalgia rheumatic (PMR).

        Presence of at least one of the following: Temporal artery biopsy revealing features of
        GCA; Evidence of large-vessel vasculitis by angiography or cross-sectional imaging.

          -  Active GCA within 6 weeks of Randomization (Baseline) where active disease is defined
             by an ESR &gt;=30 mm/hr or CRP &gt;=1 mg/dL AND the presence of at least one of the
             following:

        Unequivocal cranial symptoms of GCA; Unequivocal symptoms of PMR; Other features judged by
        the clinician investigator to be consistent with GCA or PMR flares.

          -  At screening, receiving or able to receive prednisone 20-60 mg/day for the treatment
             of active GCA.

          -  Clinically stable GCA disease at baseline such that the subject is able to safely
             participate in the blinded prednisone taper regimen in the opinion of the
             investigator.

          -  Practicing acceptable methods of birth control if a female of child-bearing potential.

          -  No evidence of active or latent infection with Mycobacterium tuberculosis (TB).

        Exclusion Criteria:

          -  Are pregnant or breastfeeding.

          -  Recent (within the past 12 weeks) or planned major surgery that would impact on study
             procedures or assessments.

          -  Organ transplantation recipients (except corneas within 3 months prior to baseline
             visit).

          -  Had prior treatment with any of the following:

        Systemic immunosuppressives) within 4 weeks of baseline; Biologic agents targeted at
        reducing tumor necrosis factor-alpha (TNF-alpha) within 2-8 weeks of baseline, depending on
        the agent; Any prior use of tocilizumab or other anti-IL-6 agents; B-cell depleting agents
        (eg, rituximab) within 12 months prior to baseline or longer if B cell counts have not
        returned to normal range or baseline levels; Cytotoxic drugs such as cyclophosphamide,
        chlorambucil, nitrogen mustard, or other alkylating agents within 4 weeks of baseline;
        Abatacept within 8 weeks of baseline; Tofacitinib within 4 weeks of baseline; Methotrexate
        use within 2 weeks of baseline.

        Methylprednisolone &gt; 100 mg/day intravenous (IV) (or equivalent) within 8 weeks of
        baseline.

          -  History of severe allergic reactions to monoclonal antibodies, human proteins, or
             excipients.

          -  Evidence of serious concomitant disease, which in the opinion of the investigator
             makes them unsuitable for participation in the study.

          -  Major ischemic event, unrelated to GCA, within 12 weeks of screening.

          -  Marked baseline prolongation of corrected QT (QTc) interval &gt;= 450 milliseconds (msec)
             (QTc by Bazett's formula [QTcB ]or QTc by Fridericia's formula [QTcF] ), history of
             Torsade de Pointes, family history of long QT syndrome, history of second or third
             degree heart block.

          -  Current liver disease that could interfere with the trial

          -  History of or current active diverticulitis, inflammatory bowel disease, or other
             symptomatic gastrointestinal tract condition that might predispose to bowel
             perforation.

          -  History of known demyelinating diseases such as multiple sclerosis or optic neuritis.

          -  Active infections, or history of recurrent infections or have required management of
             acute or chronic infections, as follows:

        Currently on any suppressive therapy for a chronic infection, history or suspicion of
        chronic infection, hospitalization for treatment of infection within 60 days of the
        baseline visit, or use of parenteral (IV) or intra-muscular [IM]) antimicrobials within 60
        days of baseline or oral antimicrobials within 30 days of baseline

          -  Primary or secondary immunodeficiency or any other autoimmune disease.

          -  Human immunodeficiency virus (HIV) infection, hepatitis C or hepatitis B infection

          -  Live virus or bacterial vaccination within 3 months before the first administration of
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Abbach</city>
        <zip>93077</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kirchheim unter Teck</city>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timaru</city>
        <zip>7910</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-312</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-121</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westcliff-on-Sea</city>
        <state>Essex</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wirral</city>
        <state>Merseyside</state>
        <zip>CH49 9PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bury St. Edmunds</city>
        <state>Suffolk</state>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reading</city>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Giant Cell Arteritis, Sirukumab, Prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

